Pharmaceutical Investing Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity
Pharmaceutical Investing Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
